Hemodynamic long-term results after medical and surgical therapy of hypertrophic cardiomyopathies. 1987

B Lösse, and F Loogen, and H D Schulte
Dept. of Cardiology, Pneumology and Angiology, University of Düsseldorf, F.R.G.

The therapeutic effectiveness of propranolol, verapamil and surgery (transaortal subvalvular myectomy) in hypertrophic cardiomyopathy was assessed in 100 patients with hypertrophic obstructive cardiomyopathy (HOCM) and 12 patients with hypertrophic non-obstructive cardiomyopathy (HNCM) by means of exercise tests with hemodynamic measurements. The effects of propranolol were assessed in 13 HOCM patients, of verapamil in 68 HOCM patients and 12 HNCM patients, and of surgery in 31 HOCM patients after a mean of 3 to 9 months. Of the 68 verapamil-treated patients, 23 were reexamined once more after a mean of 38 months. Ten of the 31 surgically treated patients were reexamined after a mean of 52 months. In the studies performed within the first year of medical treatment or after surgery, verapamil was clinically and hemodynamically superior to propranolol, but not as effective as surgical treatment. Functional limitation according to the NYHA classification improved after propranolol in 31% of the patients, after verapamil in 41%, and after surgery in 94% of the cases. Improvements by more than one NYHA class were observed exclusively after surgical treatment. Maximal exercise capacity was, on average, not changed after propranolol, but increased after verapamil and, more substantially, after surgery. These different responses to treatment could be attributed to hemodynamic changes, especially concerning heart rate, stroke volume, cardiac output, arterio-venous oxygen difference and pulmonary artery pressure. In the case of verapamil, the beneficial hemodynamic effects occurred independently of the site of intraventricular obstruction in HOCM (subvalvular or midventricular), but seemed to be superior in HOCM as compared to HNCM. The late reexaminations, an average of 38 months after beginning verapamil treatment and 52 months after surgery, demonstrated that the initial salutary clinical and hemodynamic effects of verapamil were not maintained during long-term follow-up in the majority of patients, whereas they persisted or even intensified during long-term observation after surgery.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B Lösse, and F Loogen, and H D Schulte
June 1996, Archives des maladies du coeur et des vaisseaux,
B Lösse, and F Loogen, and H D Schulte
August 1999, The Thoracic and cardiovascular surgeon,
B Lösse, and F Loogen, and H D Schulte
July 1965, Minerva pediatrica,
B Lösse, and F Loogen, and H D Schulte
September 1981, Japanese circulation journal,
B Lösse, and F Loogen, and H D Schulte
September 1991, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen,
B Lösse, and F Loogen, and H D Schulte
January 1976, The Journal of cardiovascular surgery,
B Lösse, and F Loogen, and H D Schulte
August 2002, Zentralblatt fur Chirurgie,
B Lösse, and F Loogen, and H D Schulte
November 1987, The Journal of thoracic and cardiovascular surgery,
B Lösse, and F Loogen, and H D Schulte
June 1973, The American journal of cardiology,
B Lösse, and F Loogen, and H D Schulte
February 1999, Forschende Komplementarmedizin,
Copied contents to your clipboard!